Research will continue into Paxman’s cryocompression technology to offer treatment for chemotherapy-induced peripheral neuropathy – a market of approximately 1.5 million patients at any one time.
Currently, there is not any known cure or prevention for peripheral neuropathy, a long term and debilitating side effect that causes financial burden not only on the individual, but the economy as a whole.
Paxman announced the launch of clinical trials in Singapore and the USA (with the SWOG Cancer Research Network) in its 2022 end of year report, using 100 Paxman Limb Cryocompression Systems, which can potentially provide further evidence in support of cryocompression methods.
Paxman believes strongly in diversity and inclusion and is currently supporting clinical trials into the efficacy of scalp cooling for people of colour. While there is significant anecdotal evidence to show that scalp cooling can be efficacious for black and brown patients, there is a woeful lack of research providing evidence and the adapted protocols around hair preparation and care that will make the treatment successful.
One in two people will unfortunately receive a cancer diagnosis in their lifetime, meaning everyone’s life will be impacted by it in some way, whether it’s themselves or someone they know. Paxman are driven to ensure that people aren’t having to face traumatic side effects traditionally associated with cancer treatment wherever possible. Chemotherapy hair loss isn’t inevitable anymore.
An investment in Paxman means an investment in improving the lives of hundreds of thousands of cancer patients across the world. Investment in Paxman’s medical devices contributes to reducing the traumatic side effects of chemotherapy in patients and improving healthcare outcomes.
Our senior leadership team are integral to Paxman’s success. Their wealth of experience and expertise combined with a commitment to excellence is what helps drive the business’s growth. Covering the core functions within the business – regulation, sales, production, marketing and finance, Paxman’s teams continue to confidently grow supported by strong leadership.
